Bayer files BLA for hemophilia A drug; Novo backs Acesion; Cambridge Major Labs plans $20M expansion;

Biotech News

@FierceBiotech: Amgen vet reveals stealth startup Flexus, backed by $38M from Kleiner Perkins, Celgene. News | Follow @FierceBiotech

@JohnCFierce: Auspex's Huntington's drug hits the mark in Phase III. Report | Follow @JohnCFierce

@DamianFierce: SV wealthbro Sean Parker pledges $24M to allergy research. Release | Still no word on his last effort. More | Follow @DamianFierce

> Bayer HealthCare has filed a Biologics License Application for BAY 81-8973, a recombinant Factor VIII hemophilia A compound, with the FDA. Release

> Copenhagen-based Acesion Pharma has raised 15.2 million DKK in new equity from Novo A/S and Broadview Ventures. Release

> Cambridge Major Laboratories in Wisconsin is planning a $20 million expansion. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Roche launches point-of-care, PCR molecular diagnostic system from $450M deal for iQuum. Report | Follow @FierceMedDev

@EmilyWFierce: Philips to acquire Volcano for $1.2B to expand in image-guided therapy. Report from Reuters | Follow @EmilyWFierce

> First pathogen reduction system for plasma approved by FDA. Article

> Smartphone plug-in launched for diagnosing ear infections. Item

Pharma News

@FiercePharma: Speaking of special reports, here's our newest: The top 10 patent expirations of 2015. Feature | Follow @FiercePharma

@EricPFierce: ICYMI: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. More | Follow @EricPFierce

@CarlyHFierce: Happy Hanukkah, #Pharma... here's a list of next year's biggest patent expirations. Article | Follow @CarlyHFierce

> Novartis sues Cipla for ignoring its COPD drug patents. More

> Gilead chief racks up best-CEO laurels for Sovaldi-fueled 2014. Report

> Mylan, Actavis prevail in Celebrex exclusivity fight, pushing Teva aside. Story

> Belgium's UCB calls it quits on $1.53B sale of U.S. generic drug unit. Article

Drug Delivery News

> Study: Patients don't know how to use drug delivery devices. More

> Sanofi's newly approved intradermal quadrivalent Fluzone forgoes the shot. Item

> Molecular 'hats' disguise peptides until activated with UV light at a target. Article

> MIT spinoff Microchips finishes development of its birth control, osteoporosis implant. Story

> RNAi specialist Alnylam to focus on three therapeutic areas. Report

Diagnostics News

> Roche expands use of next-gen blood tests for organ and tissue screening. Report

> FDA approves diagnostic to spot blood cancer-causing virus. Story

> Ortho-Clinical Diagnostics launches Astute Medical's acute kidney injury test in U.S. hospitals. Item

> Ariosa Diagnostics nabs expanded national coverage for noninvasive prenatal test. Article

> Roche scoops up AvanSci Bio tissue dissection technology to bolster molecular Dx offerings. More

Pharma Marketing News

> Point-of-care marketing could shoot past DTC as pharma's latest trend. Report

> Marketing lesson from Actavis' Namenda ruling: For a hard switch, keep your mouths shut. More

> Actavis revs up new commercial team for post-Allergan-merger sales race. Story

> More CEO watchers put Gilead's Martin on their 'best of 2014' lists. Item

> Sanofi, Regeneron lay groundwork for PCSK9 rollout with Cholesterol Counts campaign. Article

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.